These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
409 related items for PubMed ID: 10706092
1. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Cancer Res; 2000 Feb 15; 60(4):847-53. PubMed ID: 10706092 [Abstract] [Full Text] [Related]
2. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373 [Abstract] [Full Text] [Related]
3. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Pollack IF, Erff M, Ashkenazi A. Clin Cancer Res; 2001 May 01; 7(5):1362-9. PubMed ID: 11350907 [Abstract] [Full Text] [Related]
4. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J. J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886 [Abstract] [Full Text] [Related]
5. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Fan QL, Zou WY, Song LH, Wei W. Cancer Chemother Pharmacol; 2005 Feb 01; 55(2):189-96. PubMed ID: 15290100 [Abstract] [Full Text] [Related]
6. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151 [Abstract] [Full Text] [Related]
8. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC. Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300 [Abstract] [Full Text] [Related]
15. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K. Br J Cancer; 2003 Jan 27; 88(2):298-306. PubMed ID: 12610517 [Abstract] [Full Text] [Related]
19. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639 [Abstract] [Full Text] [Related]
20. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. J Urol; 2001 Jan 15; 165(1):263-70. PubMed ID: 11125422 [Abstract] [Full Text] [Related] Page: [Next] [New Search]